SecBot SecBot
SECBOTREPLAY Home › Report › PDSB

PDSB · PDS Biotechnology announced preliminary data from a trial using its…

PDS Biotechnology Corporation · PRESS-RELEASE filed Apr 15, 2026 at 08:45 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Apr 15, 2026 at 08:45 ET

PDS Biotechnology announced preliminary data from a trial using its PDS01ADC technology, showing a 78% objective response rate and over 80% two-year survival rate, compared to 35% and ~35% respectively in a parallel trial without PDS01ADC. These results suggest a potentially significant clinical improvement for the company's cancer therapy platform.

  • PDS01ADC trial showed 78% objective response rate vs 35% in control arm
  • Two-year survival rate exceeded 80% with PDS01ADC vs ~35% without
  • Data appears to demonstrate strong efficacy signal for PDSB's ADC platform

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access